[1] |
YANG Lei, WEI Fen, ZHANG Kai, QIU Jing-jing, WANG Ying-ying, DU Wei-xin, LU Jin-biao, TAO Li-feng, PU Jiang.
Stability and efficacy study of recombinant Mycobacterium tuberculosis fusion protein (EC)
[J]. Chinese Journal of Antituberculosis, 2020, 42(8): 799-806.
|
[2] |
ZHANG Kai, TAO Li-feng, WEI Fen, DU Wei-xin, QIU Jing-jing, CHEN Wei, CHEN Bao-wen, ZHU Yin-meng, CHENG Xing, SU Cheng, ZHONG Zai-xin, LU Jin-biao, PU Jiang.
Immune characteristics and preclinical animal safety studies of recombinant Mycobacterium tuberculosis fusion protein(EC)
[J]. Chinese Journal of Antituberculosis, 2020, 42(8): 807-813.
|
[3] |
ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang.
Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein
[J]. Chinese Journal of Antituberculosis, 2020, 42(8): 814-820.
|
[4] |
YANG Lu-qi, SHEN Ming-yi, SHA Wei, CHEN Ying-ying, WANG Ying.
Research progress in immunoprotective mechanism of bacille Calmette-Guérin and vaccine development strategies
[J]. Chinese Journal of Antituberculosis, 2020, 42(8): 863-868.
|
[5] |
XIE Li, GAO Jing-tao, MA Li-ping, ZHANG Li-qun, KONG Zhong-shun, WU Xiao-guang, LIU Rong-mei, CHEN Hong-mei, SONG Yan-hua, LI Xue-lian, Huang Mai-ling, LI Qiang, Lv Zi-zheng, LIu Yv-hong, Gao Meng-qiu.
Effect of bedaquiline-containing regimen on QT interval in patients with multidrug-resistant tuberculosis
[J]. Chinese Journal of Antituberculosis, 2020, 42(7): 687-694.
|
[6] |
ZHANG Jing, CHEN Xi, WANG Bin, FU Lei, LU Yu, CHEN Xiao-you.
Establishment of modified propidium monoazide (PMAxx)-quantitative PCR assay and its application for identification of antituberculosis drug activity
[J]. Chinese Journal of Antituberculosis, 2020, 42(5): 472-480.
|
[7] |
GAO Tian-hui,SHU Wei,GAO Jing-tao,LU Yu,LI Qi.
Analysis of clarithromycin resistance and its influencing factors in 254 patients with drug-resistant tuberculosis
[J]. Chinese Journal of Antituberculosis, 2020, 42(3): 259-265.
|
[8] |
CHEN Hao,WU Nan-nan,HU Wen-hui,YANG Zhong-jin.
Research progress of new targets for antituberculosis agents
[J]. Chinese Journal of Antituberculosis, 2020, 42(3): 286-292.
|
[9] |
WANG Jing,ZHANG Meng,HE Jian-qing.
Clostridium difficile-associated diarrhea caused by anti-tuberculosis drugs: a case report and literature review
[J]. Chinese Journal of Antituberculosis, 2020, 42(3): 293-296.
|
[10] |
QIU Lei,ZHANG Shao-yan,GUO Xiao-yan,FU Ji-you,TIAN Li-ming,ZHANG Hui-yong,LU Zhen-hui.
Clinical value of chemotherapy regimen and Qinbudan tablet on the retreatment of retreated smear-positive pulmonary tuberculosis
[J]. Chinese Journal of Antituberculosis, 2020, 42(2): 108-114.
|
[11] |
WANG Xue-di,JIANG Feng,DAI Qian-lan,WANG Jing,WANG Dong-mei..
Comparative analysis on drug-induced liver injury of the combination of traditional Chinese and Western medicine and single Western medicine in tuberculosis treatment (Literature review 2000-2019)
[J]. Chinese Journal of Antituberculosis, 2020, 42(2): 126-132.
|
[12] |
LI Meng, LU Li-ping, JIANG Qi, HONG Jian-jun, GAO Qian, YANG Chong-guang, GUO Xiao-qin.
Analysis of the types and expense of therapeutic drugs for pulmonary tuberculosis in Songjiang District of Shanghai
[J]. Chinese Journal of Antituberculosis, 2020, 42(12): 1329-1332.
|
[13] |
TANG Liang, BAO Yu-cheng, ZHANG Wen-long.
Effects of anti-tubercular agents on intestinal flora and its influence on the organism
[J]. Chinese Journal of Antituberculosis, 2020, 42(12): 1333-1338.
|
[14] |
LIU Er-yong, ZHOU Lin, XUE Xiao, LIU Chun-fa, BAI Li-qiong, LU Wei, ZHANG Tian-hua, CHENG Shi-ming.
Evaluation of treatment effect and safety of rifampicin capsule (Ⅱ) on pulmonary tuberculosis
[J]. Chinese Journal of Antituberculosis, 2020, 42(10): 1092-1099.
|
[15] |
Xi CHEN,Zhong-quan LIU,Bin WANG,Hui ZHU,Lei FU,Yuan-yuan LI,Yu LU.
Evaluation of antituberculosis activities of 14 antituberculosis drugs in macrophage
[J]. Chinese Journal of Antituberculosis, 2019, 41(9): 993-998.
|